Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 17/20 | 0.81 |
| ▸ | DRD2 | P14416 | 2/20 | 0.81 |
| ▸ | HTR2A | P28223 | 2/20 | 0.81 |
| ▸ | HTR2C | P28335 | 2/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.81 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.81 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.48 |
| ▸ | HTR1B | P28222 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palosuran SCHEMBL29441424 | 0.90 | UTS2R (1.00) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| Palosuran SCHEMBL1363480 | 0.90 | UTS2R (1.00) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| SCHEMBL4833941 | 0.89 | UTS2R (0.71) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| Palosuran SCHEMBL5265025 | 0.87 | UTS2R (1.00) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| Palosuran SCHEMBL29441419 | 0.87 | UTS2R (1.00) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| Palosuran SCHEMBL1363165 | 0.86 | UTS2R (0.98) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| Palosuran SCHEMBL1364658 | 0.86 | UTS2R (0.98) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| Palosuran SCHEMBL1364002 | 0.86 | UTS2R (0.98) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| SCHEMBL4856925 | 0.85 | UTS2R (0.90) | UTS2RDRD2HTR2AHTR2CADRA2A | |
| Palosuran SCHEMBL5935080 | 0.85 | UTS2R (0.86) | UTS2RDRD2HTR2AHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-7265122-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265122-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265122-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2004078114-A2 | PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE, AND NAPHTHALENE UROTENSIN-II RECEPTOR ANTAGONISTS. | ENCYSIVE PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | UTS2R 1/4885DRD2 1127/4885HTR2A 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.